NCT02822105View on ClinicalTrials.gov

Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

April 30, 2017

Study Completion Date

November 30, 2017

Conditions

Flu

Interventions

BIOLOGICAL

the H3N2 M2SR monovalent influenza vaccine

The H3N2 Bris10 M2SR influenza vaccine candidate (Bris10 M2SR) is formulated to contain different levels of an M2-deleted non-replicating influenza virus expressing the HA and NA genes of influenza strain A/Brisbane/10/2007.

OTHER

Placebo

saline

Trial Locations (1)

66219

JCCT, Lenexa